Literature DB >> 3127569

Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis.

A L Smith1, G Redding, C Doershuk, D Goldmann, E Gore, B Hilman, M Marks, R Moss, B Ramsey, T Rubio.   

Abstract

We sought to define objective indicators of the resolution of Pseudomonas aeruginosa endobronchial infection in patients with cystic fibrosis. We prospectively studied 75 patients admitted for treatment of a pulmonary exacerbation and quantitated sputum bacterial density, DNA content, and the concentration of albumin and total protein in sputum, and compared these values with clinical evaluation. Eleven of the 75 patients had systemic signs, fever, and leukocytosis, which we arbitrarily defined as due to endobronchial infection. At the end of hospitalization, these 11 patients were afebrile, had peripheral leukocyte counts in the normal range, and were judged improved. Sputum P. aeruginosa density, DNA content, and total protein content on admission were similar in the two illness groups. Hospitalization and parenteral antibiotic administration for an average of 14.6 days were associated with improved pulmonary function in all 75 subjects (P values for forced vital capacity, forced expiratory volume at 1 second, and peak expiratory flow rate were all less than 0.001). With improvement, there was a decrease in sputum P. aeruginosa density (mean of both groups decreased from 10(7.80) CFU/g on admission to 10(5.96) CFU/g; P less than 0.001), and a decreased DNA concentration (overall mean 4.73 +/- 4.75 on admission to 2.76 +/- 2.49 mg/g; P less than 0.002). The decrease in sputum total protein concentration for both groups was not significant (overall mean 60.5 +/- 48.4 to 43.9 +/- 38.2 mg/g; P = 0.06). Sputum albumin concentrations did not change in either group. We conclude that in cystic fibrosis subjects with a pulmonary exacerbation, bacterial density, sputum DNA and protein content decrease with hospitalization and parenteral antibiotic therapy. At the end of treatment, these indices of sputum infection and inflammation correlate with improved pulmonary function and clinical improvement. These changes are independent of the presence or absence of fever on admission.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3127569     DOI: 10.1016/s0022-3476(88)80165-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  32 in total

1.  Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.

Authors:  Christiane Beckmann; Mitchell Brittnacher; Robert Ernst; Nicole Mayer-Hamblett; Samuel I Miller; Jane L Burns
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 2.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

3.  Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.

Authors:  Theresa A Laguna; Brandie D Wagner; Heidi K Luckey; Shelley A Mann; Scott D Sagel; Warren Regelmann; Frank J Accurso
Journal:  Chest       Date:  2009-06-30       Impact factor: 9.410

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation.

Authors:  Theresa A Laguna; Brandie D Wagner; Barry Starcher; Heidi K Luckey Tarro; Shelley A Mann; Scott D Sagel; Frank J Accurso
Journal:  Pediatr Pulmonol       Date:  2012-03-19

6.  Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis.

Authors:  S P Conway; M N Pond; A Watson; C Etherington; H L Robey; M H Goldman
Journal:  Thorax       Date:  1997-11       Impact factor: 9.139

7.  In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

Authors:  John J LiPuma; Sivaprakash Rathinavelu; Bridget K Foster; Jordan C Keoleian; Paul E Makidon; Linda M Kalikin; James R Baker
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 8.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

9.  Expression of S100A12 (EN-RAGE) in cystic fibrosis.

Authors:  D Foell; S Seeliger; T Vogl; H-G Koch; H Maschek; E Harms; C Sorg; J Roth
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

10.  Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis.

Authors:  Tacjana Pressler
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.